Open AccessSystematic Evaluation and Meta-Analysis of the Efficacy and Safety of Shenfu Injection in the Treatment of Septic Cardiomyopathy
Author(s) -
Rui Wu,
Meng Li
Publication year - 2022
Publication title -
proceedings of anticancer research
Language(s) - English
Resource type - Journals
eISSN - 2208-3553
pISSN - 2208-3545
DOI - 10.26689/par.v6i1.2883
Subject(s) - medicine , ejection fraction , meta analysis , cardiomyopathy , troponin , sepsis , cardiac function curve , adverse effect , incidence (geometry) , cardiology , anesthesia , heart failure , myocardial infarction , physics , optics
Objective: To evaluate the efficacy and safety of Shenfu injection in the treatment of septic cardiomyopathy. Methods: Literatures on Shenfu injection for the treatment of sepsis published from the establishment of each database to December 31, 2020, were searched by computer; Cochrane risk-of-bias tool was used for evaluating the quality of literatures, and Review Manager 5.4 software was used for meta-analysis. Results: Twenty random controlled trials (RCTs) were included, with a total of 1,179 patients; the meta-analysis showed that the routine treatment of Western medicine combined with Shenfu injection can reduce the 28-day mortality, the length of hospital stay, cardiac troponin I (cTnI), and N-terminal pro-brain natriuretic peptide (NT-proBNP) as well as improve the left ventricular ejection fraction (LVEF) with low incidence of adverse reactions. Conclusion: Western medicine combined with Shenfu injection can further reduce myocardial injury in patients with sepsis and improve cardiac function as well as the prognosis of patients with septic cardiomyopathy.